Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06967181 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 2026 to Dec 2027
    • Primary endpoints: 4 to 5
    • Study completion date: Nov 2026 to Dec 2027
    • Study description revised
    v5
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v4
  3. Study sites: 1 to 3v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2025 to May 14, 2025
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.
Trial Details
NCT Number NCT06967181
Lead Sponsor CyanVac LLC
Conditions
(from sponsor)		 Mumps
Related terms Mumps
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov